Heart failure & cardiomyopathies
The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy—the IRON-CRT trial
Authors' conclusion
Treatment with FCM in HFrEF patients with iron deficiency and persistently reduced LVEF after CRT results in an improvement of cardiac function measured by LVEF, LVESV, and cardiac force-frequency relationship.
Study context
- Population
- Symptomatic heart failure with reduced ejection fraction (HFrEF) patients with iron deficiency and persistently reduced LVEF (<45%) at least 6 months after cardiac resynchronization therapy (CRT) implant
- Participants
- 75 patients
- Comparison
- Ferric carboxymaltose (FCM) vs standard of care
- FCMn = 37
- Standard of care (SOC)n = 38reference
- Primary endpoint
- Change in LVEF by 3D echocardiography
- Follow-up
- 3 months
Methodological detailsdouble-blind
- Double-blind
Primary result
As reported in the abstract
FCM
+4.22
95% CI +3.05%; +5.38% · %
SOC
−0.23
95% CI −1.44%; +0.97% · %
P < 0.001
Secondary outcomes
mL
| Outcome | FCM | SOC | P value |
|---|---|---|---|
| Change in LVESV · 3 months | −9.72 (95% CI −13.5 mL; −5.93 mL) | −1.83 (95% CI −5.7 mL; 2.1 mL) | P = 0.001 |
| Change in LVEDV · 3 monthsNo improvement | P = 0.748 |
Force-frequency relationship (CCI slope during incremental biventricular pacing) · 3 months
- Negative force-frequency relationship in both groups at baseline; FCM improved CCI slope, with a positive force-frequency relationship at 3 months
Functional status (KCCQ) and exercise capacity (peak oxygen consumption)
- Improved by FCM
Original publication
The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy—the IRON-CRT trial. Eur Heart J. Published 29 June 2021. doi:10.
Summarised from the published abstract; every number is checked against it